AEON Biopharma: Of The Current Report On Form 8k Filed By Aeon Biopharma, Inc. (the Company ) On July 27, 2023, (the Original Report ), In Which The Company Reported, Among Other Events, The Completion Of The Transactions. This Amendment No. 1 Amends Items 9.01(a) And 9.01(b) In The Original Report To Include (a) The Unaudited Condensed Consolidated Financial Statements Of Aeon Biopharma, Inc., A Delaware Corporation Formerly Known As Aeon Biopharma, Inc. ( Old Aeon ), As Of June 30, 2023 And For The Three And Six Months Ended June 30, 2023 And 2022, And (b) The Unaudited Pro Forma Condensed Combined Financial Information Of Priveterra Acquisition Corp. ( Priveterra ) And Old Aeon As Of And For The Six Months Ended June 30, 2023 And For The Year Ended December 31, 2022. This Amendment No. 1 Does Not Amend Any Other Item Of The Original Report Or Purport To Provide An Update Or A Discussion Of Any Developments At The Company Subsequent To The Filing Date Of The Original Report

Show full article

This functionality is available for registred users only

• Full name
  AEON Biopharma Inc
• Registration country
  USA
• Industry
  Other Financial Institutions
• М/S&P/F
  *** / *** / ***